Laboratory Reference Ranges and Functional Deficiency
This section covers the systematic gap between population-derived laboratory reference intervals and the thresholds required for optimal cellular function in chronically ill individuals. Evidence spans iron, magnesium, vitamin B12, vitamin D, and thyroid hormones.
1 Vaucher et al. 2012 — Iron Supplementation in Nonanemic Women with Low Ferritin (RCT)
Full Citation:: Vaucher P, Druais PL, Waldvogel S, Favrat B. Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial. CMAJ. 2012;184(11):1247–54. DOI:: 10.1503/cmaj.110950 PMID:: 22777991 Study Design:: Multicentre parallel RCT, 44 primary care practices, France; observer-blinded Sample Size:: n=198 (102 iron, 96 placebo), ages 18–53 Ferritin Cutoff:: <50 µg/L with normal hemoglobin (>12.0 g/dL) Key Findings::
- Ferrous sulfate 80 mg elemental iron daily × 12 weeks reduced fatigue score 47.7% vs 28.8% placebo (p=0.02)
- No significant improvement in quality of life, depression, or anxiety
- Iron therapy raised hemoglobin, raised ferritin, reduced soluble transferrin receptorReference Range Problem:: WHO iron deficiency threshold is <15 µg/L; most clinical labs flag deficiency only below 12–15 µg/L. This RCT demonstrates fatigue benefit at ferritin levels up to 50 µg/L — more than 3× the WHO cutoff. Patients with ferritin 16–49 µg/L would typically be told their iron is “normal.” Certainty Assessment::
- *Quality:* High — CMAJ, peer-reviewed RCT, independent
- *Sample:* n=198, female only, France primary care
- *Replication:* Supported by Krayenbuehl 2011 and Yokoi 2017 meta-analysis
- *Limitations:* Women only; no ME/CFS patients; short follow-up (12 weeks); no objective performance measures improved2 Krayenbuehl et al. 2011 — Intravenous Iron for Fatigue in Nonanemic Women (RCT)
Full Citation:: Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood. 2011;118(12):3222–7. DOI:: 10.1182/blood-2011-04-346304 PMID:: 21705493 Study Design:: Randomized, double-blind, placebo-controlled trial Sample Size:: n=90 premenopausal women; ferritin ≤50 ng/mL; hemoglobin ≥120 g/L Key Findings::
- In subgroup with ferritin ≤15 ng/mL: fatigue decreased 1.8 (iron) vs 0.4 (placebo), p=0.005
- 82% vs 47% reported subjective improvement in that subgroup (p=0.03)
- Full cohort (up to 50 ng/mL) showed smaller overall effect
- Adverse events 21% iron group vs 7% placeboReference Range Problem:: Enrollment threshold of ≤50 ng/mL is well above standard lab deficiency cutoffs (typically 12 ng/mL for women). Strongest benefit was in the ≤15 ng/mL subgroup, confirming functional importance of the near-deficient range that most labs classify as “normal.” Certainty Assessment::
- *Quality:* High — *Blood* journal, double-blind RCT
- *Sample:* n=90, women only
- *Replication:* Consistent with Vaucher 2012
- *Limitations:* Subgroup analysis for main effect; women only; single centre3 Yokoi and Konomi 2017 — Meta-Analysis of IDWA and Fatigue
Full Citation:: Yokoi K, Konomi A. Iron deficiency without anaemia is a potential cause of fatigue: meta-analyses of randomised controlled trials and cross-sectional studies. British Journal of Nutrition. 2017;117(10):1422–31. DOI:: 10.1017/S0007114517001349 PMID:: 28625177 Study Design:: Systematic review + two meta-analyses (6 RCTs, 6 cross-sectional studies) Key Findings::
- RCT pool: iron supplementation significantly reduced fatigue in IDWA (effect size 0.33, p\<0.0001)
- Cross-sectional pool: IDWA status did not significantly predict fatigue (effect size 0.10, p=0.362)
- Interpretation: supplementation improves fatigue; cross-sectional IDWA status alone does not reliably stratify fatigued from non-fatigued individualsReference Range Problem:: Ferritin thresholds defining IDWA in included studies ranged from <12 to <50 µg/L across different research teams, confirming there is no consensus on where “normal” iron stores end and functional deficiency begins. Certainty Assessment::
- *Quality:* Medium-high — *British Journal of Nutrition*, systematic methods
- *Sample:* Pooled from 12 studies
- *Replication:* Summarizes existing evidence
- *Limitations:* Heterogeneous ferritin cutoffs; no ME/CFS-specific data; publication bias possible4 Al-Naseem et al. 2021 — Iron Deficiency Without Anaemia: A Diagnosis That Matters
Full Citation:: Al-Naseem A, Sallam A, Choudhury S, Thachil J. Iron deficiency without anaemia: a diagnosis that matters. Clinical Medicine (London). 2021;21(2):107–113. DOI:: 10.7861/clinmed.2020-0582 PMID:: 33762368 Study Design:: Narrative review Key Findings::
- IDWA is at least twice as common as iron deficiency anemia, yet remains clinically underrecognized
- WHO cutoff (\<15 µg/L) misses many clinically significant cases; \<30 µg/L has high specificity and sensitivity for absent bone marrow iron stores
- In inflammatory conditions (relevant to ME/CFS): threshold rises to 100 µg/L (with TSAT \<20% as confirmatory marker)
- Calls for IDWA to be recognized as a standalone clinical diagnosisCertainty Assessment::
- *Quality:* Medium — *Clinical Medicine* (Royal College of Physicians), peer-reviewed narrative review
- *Sample:* Review, no primary data
- *Limitations:* Narrative review; no ME/CFS data; practical guidance for general medicine5 Workinger et al. 2018 — Challenges in the Diagnosis of Magnesium Status
Full Citation:: Workinger JL, Doyle RP, Bortz J. Challenges in the diagnosis of magnesium status. Nutrients. 2018;10(9):1202. DOI:: 10.3390/nu10091202 PMID:: 30200431 Study Design:: Narrative review Key Findings::
- Only ~1% of total body magnesium is in blood; 99% is intracellular (53% bone, 27% muscle, 19% other tissues)
- Standard serum magnesium assay has "no reliable correlation" with total body or tissue magnesium levels
- Serum levels are tightly regulated by renal excretion and remain "normal" even when total body stores are depleted
- No validated rapid bedside test for true magnesium status exists
- RBC magnesium is a better (but imperfect and non-standardized) proxy
- Estimated 45% of Americans are magnesium-deficient by dietary intake measures despite frequently normal serum resultsReference Range Problem:: The standard serum magnesium reference interval measures the wrong compartment for chronic deficiency detection. Patients with textbook magnesium deficiency symptoms (fatigue, muscle cramps, sleep disruption) routinely present with “normal” serum magnesium because the body preserves serum levels at the expense of tissue stores. Certainty Assessment::
- *Quality:* Medium — *Nutrients* (MDPI), MEDLINE-indexed, systematic narrative methods
- *Sample:* Review, no primary data
- *Limitations:* No primary data; MDPI open-access journal; recommendation to use RBC magnesium is not uniformly endorsed6 Russell-Jones 2022 — Functional Vitamin B12 Deficiency in Chronic Fatigue Syndrome
Full Citation:: Russell-Jones G. Functional vitamin B12 deficiency in chronic fatigue syndrome. International Journal of Psychiatry. 2022;7(3):153–158. DOI:: 10.33140/IJP (journal prefix; article-level DOI not confirmed in PubMed) PMID:: Not indexed in PubMed Study Design:: Observational comparison, n=350 CFS individuals Key Findings::
- Majority of CFS patients showed functional B12 deficiency markers (elevated methylmalonic acid, urinary metabolites) despite normal to elevated serum B12
- Termed "paradoxical vitamin B12 deficiency" — serum B12 does not reflect functional B12 status
- B2 (riboflavin) co-deficiency proposed as mechanism: riboflavin is required for functional B12 activity
- Serum B12 reference ranges measure circulating cobalamin, not intracellular utilizationCertainty Assessment::
- *Quality:* Low — not PubMed-indexed; Opast Publishing (lower-tier open-access); peer review quality uncertain
- *Sample:* n=350, no control group details confirmed
- *Replication:* Not independently replicated at this level of specificity
- *Limitations:* Low-tier journal; methods not fully validated; treat as hypothesis-generating only; use `speculation` environment7 Charoenngam and Holick 2020 — Immunologic Effects of Vitamin D
Full Citation:: Charoenngam N, Holick MF. Immunologic effects of vitamin D on human health and disease. Nutrients. 2020;12(7):2097. DOI:: 10.3390/nu12072097 PMID:: 32679784 Study Design:: Narrative review Key Findings::
- Classical bone-health threshold (basis for most lab reference ranges): 20 ng/mL (50 nmol/L)
- Optimal immune function threshold: 40--60 ng/mL (100--150 nmol/L)
- Active vitamin D modulates T-cell and B-cell activity, cathelicidin production, anti-inflammatory cytokines
- Significant inter-individual variation in VDR gene expression: identical serum 25(OH)D levels produce different cellular immune responsesReference Range Problem:: A 25(OH)D of 22 ng/mL is labeled “sufficient” by standard lab reference ranges (bone health threshold). The immune-optimization threshold is 2–3× higher. VDR polymorphisms mean some individuals may require substantially higher serum levels to achieve equivalent intracellular vitamin D signaling. Certainty Assessment::
- *Quality:* Medium — *Nutrients* (MDPI), MEDLINE-indexed; Holick is leading authority in field
- *Sample:* Review; draws on mechanistic, observational, and RCT data
- *Replication:* Optimal immune threshold supported by multiple independent research groups
- *Limitations:* Narrative review; Holick has disclosed commercial relationships (speaking fees); optimal immune threshold not established by large RCTs; VITAL trial showed partial benefits only8 Holick et al. 2011 — Endocrine Society Vitamin D Clinical Practice Guideline
Full Citation:: Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2011;96(7):1911–30. DOI:: 10.1210/jc.2011-0385 PMID:: 21646368 Study Design:: Evidence-based clinical practice guideline (Endocrine Society) Key Findings::
- Deficiency defined as \<20 ng/mL; insufficiency 21--29 ng/mL; sufficiency ≥30 ng/mL
- Recommends targeting 40--60 ng/mL for maximum extraskeletal (immune, cancer, cardiovascular) benefit
- Adults at risk may require 1500--2000 IU/day to achieve >30 ng/mL
- The guideline itself makes explicit that bone-health cutoffs and extraskeletal-benefit thresholds are differentCertainty Assessment::
- *Quality:* High — Endocrine Society, evidence-graded guideline, >20,000 citations
- *Replication:* Widely adopted; partially updated by 2024 Endocrine Society guideline
- *Limitations:* 2011 guideline; some extraskeletal benefit claims revised in light of subsequent RCTs (VITAL); Holick COI disclosure9 Panicker et al. 2009 — DIO2 Polymorphism, Psychological Wellbeing, and T4/T3 Response
Full Citation:: Panicker V, Saravanan P, Vaidya B, Evans J, Hattersley AT, Frayling TM, Dayan CM. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. Journal of Clinical Endocrinology & Metabolism. 2009;94(5):1623–9. DOI:: 10.1210/jc.2008-1301 PMID:: 19190113 Study Design:: Prospective genetic subgroup analysis within the Weston Area T4 T3 Study (WATTS) Sample Size:: n=552 subjects on T4 monotherapy for hypothyroidism Key Findings::
- DIO2 rs225014 CC genotype (present in 16% of the sample) associated with worse baseline psychological wellbeing on T4 alone (GHQ 14.1 vs 12.8, p=0.03)
- CC genotype showed greater benefit from T4+T3 combination therapy: +2.3 GHQ points at 3 months, +1.4 at 12 months (p=0.03 repeated-measures ANOVA)
- Critically: the CC genotype had NO impact on serum TSH, T3, or T4 levels
- DIO2 encodes type II deiodinase, which converts T4 to active T3 intracellularly in brain and pituitary; Thr92Ala substitution reduces enzyme efficiencyReference Range Problem:: TSH is the primary clinical marker of thyroid function and was completely normal in all genotype groups. Yet 16% of hypothyroid patients had measurably worse psychological function explicable only by impaired intracellular T4-to-T3 conversion — a process serum TSH cannot assess. Tissue-level thyroid hormone deficiency exists in a measurable fraction of patients despite normal serum thyroid function tests. Certainty Assessment::
- *Quality:* High — *JCEM*, prospective genetic analysis, validated study design
- *Sample:* n=552 on T4 therapy (hypothyroid patients, not general population or ME/CFS)
- *Replication:* Mixed; the Thr92Ala DIO2 polymorphism principle is supported by multiple groups; specific effect sizes contested
- *Limitations:* Hypothyroid patients only; not applicable to euthyroid individuals directly; p-values borderline (0.02--0.06); does not apply to TSH screening in general ME/CFS without known hypothyroidism10 Ruiz-Núñez et al. 2018 — Low T3 Syndrome in ME/CFS (Case-Control)
Full Citation:: Ruiz-Núñez B, Tarasse R, Vogelaar EF, Dijck-Brouwer DAJ, Muskiet FAJ. Higher prevalence of “low T3 syndrome” in patients with chronic fatigue syndrome: a case–control study. Frontiers in Endocrinology. 2018;9:97. DOI:: 10.3389/fendo.2018.00097 PMID:: 29615976 Study Design:: Case-control Sample Size:: n=98 ME/CFS patients; n=99 age/sex-matched healthy controls Key Findings::
- ME/CFS patients showed lower FT3, total T3, total T4; elevated reverse T3 percentage
- FT3 below reference range in 16/98 CFS patients vs 7/99 controls (OR 2.56, p=0.035)
- TSH was normal in all subjects — the abnormality is invisible to TSH-based screening
- Reduced deiodination function and thyroid secretory capacity in CFS group
- Pattern resembles mild non-thyroidal illness syndrome (NTIS), suggesting systemic illness suppresses T4→T3 conversion independently of primary thyroid diseaseReference Range Problem:: Standard thyroid screening uses TSH only. All ME/CFS patients in this study would be classified “euthyroid” by TSH. FT3 and reverse T3 measurements — which revealed a 2.56-fold increased risk of low T3 — are not part of routine thyroid function panels. Certainty Assessment::
- *Quality:* Medium — *Frontiers in Endocrinology* (peer-reviewed open-access; variable review quality)
- *Sample:* n=197 case-control; adequate size
- *Replication:* Not independently replicated in larger ME/CFS cohort
- *Limitations:* Case-control cannot establish causality; Frontiers publication; NTIS pattern may reflect effect rather than cause of ME/CFS11 Ott et al. 2011 — Hashimoto’s Thyroiditis: Fatigue Independent of TSH
Full Citation:: Ott J, Promberger R, Kober F, Neuhold N, Tea M, Huber JC, Hermann M. Hashimoto’s thyroiditis affects symptom load and quality of life unrelated to hypothyroidism: a prospective case-control study in women undergoing thyroidectomy for benign goiter. Thyroid. 2011;21(2):161–7. DOI:: 10.1089/thy.2010.0191 PMID:: 21186954 Study Design:: Prospective case-control (histology-confirmed Hashimoto’s as case definition) Sample Size:: n=426 euthyroid women undergoing thyroid surgery; 28 (6.6%) confirmed Hashimoto’s on histology Key Findings::
- Anti-TPO cutoff for true thyroid inflammation calculated at 121.0 IU/mL
- Women above cutoff had significantly higher symptom counts (6.7±2.5 vs 4.1±2.8, p\<0.001)
- Chronic fatigue was significantly more prevalent in the Hashimoto's group
- TSH levels were statistically identical between groups (1.7±1.3 vs 1.5±1.4 µU/mL)
- Autoimmune inflammation itself — not hypothyroidism — drives fatigue and other symptomsReference Range Problem:: Euthyroid Hashimoto’s patients have “normal” TSH by every standard reference interval. The symptom burden (including chronic fatigue) is driven by TPO antibody-mediated autoimmune activity, which is not part of standard thyroid function panels and has no established reference range for “safe” antibody levels. Certainty Assessment::
- *Quality:* High — *Thyroid* (leading specialty journal), prospective, histology-confirmed case definition
- *Sample:* n=426 total; Hashimoto's subgroup n=28 (small)
- *Replication:* Consistent with wider literature on euthyroid Hashimoto's symptom burden
- *Limitations:* Women only (surgical sample); small Hashimoto's subgroup; surgical sample may overrepresent structural thyroid disease12 Joustra et al. 2017 — Vitamin and Mineral Status in CFS/Fibromyalgia (Systematic Review)
Full Citation:: Joustra ML, Minovic I, Janssens KAM, Bakker SJL, Rosmalen JGM. Vitamin and mineral status in chronic fatigue syndrome and fibromyalgia syndrome: a systematic review and meta-analysis. PLoS One. 2017;12(4):e0176631. DOI:: 10.1371/journal.pone.0176631 PMID:: 28453534 Study Design:: Systematic review + meta-analysis; 45 studies (5 RCTs, 40 observational) Key Findings::
- No consistent differences in vitamin D, magnesium, B12, iron, zinc, or folate between CFS/FMS patients and controls using standard serum/plasma measures
- Vitamin E lower in patients vs controls, but effect disappeared in higher-quality studies
- Supplementation RCTs showed no consistent clinical improvements
- Study quality was generally poor; substantial heterogeneity
- Conclusion: "Little evidence was found to support the hypothesis that vitamin and mineral deficiencies play a role in the pathophysiology of CFS and FMS"Critical Interpretation:: This is the necessary empirical counterweight. However, the systematic review used standard serum/plasma assays — precisely the measures identified elsewhere in this section as inadequate for detecting intracellular and functional deficiencies (magnesium, B12) or for applying functional thresholds (ferritin, vitamin D). The negative finding should be read as “standard serum measures show no consistent differences,” not “no functional deficiency exists.” The two conclusions are compatible. Certainty Assessment::
- *Quality:* Medium-high — *PLoS One*, systematic methods, pre-registered
- *Sample:* 45 studies pooled
- *Limitations:* Relies entirely on serum/plasma measures; poor primary study quality; high heterogeneity; may miss functional deficiencies by design; does not address the reference range problem directly13 Pimentel et al. 2000 — SIBO Eradication Decreases CFS Symptoms (RCT)
Full Citation:: Pimentel M, Hallegua D, Chow EJ, Wallace D, Bonorris G, Lin HC. Eradication of small intestinal bacterial overgrowth decreases symptoms in chronic fatigue syndrome: a double blind, randomized study. Gastroenterology. 2000;118(4):A414. (Pimentel et al. 2000) DOI:: 10.1016/S0016-5085(00)83765-8 PMID:: Not indexed (conference abstract, Digestive Disease Week 2000) Article Type:: Double-blind, placebo-controlled RCT (conference abstract) Key Findings::
- n=31 CFS patients; 77% SIBO-positive by lactulose hydrogen breath test
- Neomycin vs placebo: no statistically significant difference between arms (underpowered)
- Breath test normalisation correlated with symptom improvement in responders
- First controlled study demonstrating high SIBO prevalence in CFS and testing eradicationConclusion:: Supports the biological plausibility of SIBO as a comorbid contributor to CFS symptoms, but the RCT was insufficiently powered to demonstrate treatment efficacy. Limitations:: Conference abstract only; never published as full peer-reviewed paper. n=31 is severely underpowered. Lactulose breath test validity is contested (see Kashyap 2024). Study is 25+ years old; replication urgently needed. Conflict of interest not assessable (abstract). ME/CFS Relevance:: Provides the only (albeit low-quality) RCT evidence for SIBO eradication in CFS specifically. Supports biological rather than functional explanation for GI symptoms. The 77% SIBO prevalence figure should be cited cautiously given methodology limitations. Certainty Assessment::
- *Quality:* Low (conference abstract, never peer-reviewed as full paper)
- *Sample:* n=31
- *Replication:* Not independently replicated
- *Score:* 0.2514 Pimentel et al. 2011 — Rifaximin for IBS-D: TARGET 1 and 2 RCTs
Full Citation:: Pimentel M, Lembo A, Chey WD, et al.; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22–32. (Pimentel et al. 2011) DOI:: 10.1056/NEJMoa1004409 PMID:: 21208106 Article Type:: Phase 3 double-blind RCT (two identically designed trials) Key Findings::
- Rifaximin 550 mg three times daily × 14 days vs placebo in IBS without constipation (IBS-D)
- Adequate relief of global IBS symptoms: 40.7% rifaximin vs 31.7% placebo (combined; p\<0.001)
- Significant relief of bloating, abdominal pain, loose/watery stools
- Effect maintained up to 10 weeks after treatment completion
- Rifaximin is minimally absorbed, acting locally in the gut lumen — low systemic adverse effectsConclusion:: Rifaximin provides modest but statistically significant and durable symptom relief in IBS-D, consistent with SIBO or dysbiosis as a contributing pathomechanism. Effect size is real but not large (NNT ≈ 11). Limitations:: IBS-D cohort, not ME/CFS-specific. Commercial funding by Salix Pharmaceuticals (disclosed). Effect size modest. Breath test not used for patient selection. Mechanism inferred (dysbiosis/SIBO), not confirmed. No long-term follow-up beyond 10 weeks. ME/CFS Relevance:: Provides highest-quality evidence that rifaximin is effective against presumed small intestinal dysbiosis — the closest proxy for SIBO treatment in ME/CFS patients who share IBS comorbidity. Supports rifaximin as a reasonable therapeutic option for ME/CFS patients with confirmed SIBO and IBS-D symptoms. Certainty Assessment::
- *Quality:* High (phase 3 RCT × 2, NEJM, large n)
- *Sample:* n≈1,200 combined
- *Replication:* Independently replicated across two trials; FDA approved
- *Score:* 0.7515 Pimentel et al. 2009 — Prokinetics Delay SIBO Relapse
Full Citation:: Pimentel M, Morales W, Lezcano S, Sun-Chuan D, Low K, Yang J. Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. Gastroenterol Hepatol (N Y). 2009;5(6):435–442. (Pimentel et al. 2009) DOI:: Not available PMID:: 20574504 | PMC: PMC2886395 Article Type:: Retrospective chart review Key Findings::
- 64 IBS-SIBO patients with confirmed clinical and breath test resolution post-antibiotic treatment
- Symptom-free days before relapse: no prevention 59.7 days; low-dose nocturnal erythromycin 138.5 days; low-dose nocturnal tegaserod 241.6 days
- Tegaserod significantly superior to erythromycin (p\<0.05) and to no prevention
- Mechanism: prokinetics stimulate MMC phase III contractions, maintaining fasting clearance of small intestinal contents
- Note: tegaserod withdrawn from US market (cardiac risk); prucalopride is the current functional replacementConclusion:: Post-eradication prokinetics meaningfully extend relapse-free intervals in IBS-SIBO, supporting their routine use to address the underlying motility deficit. Limitations:: Retrospective, small subgroups (tegaserod n=16), no blinding, IBS-SIBO proxy for ME/CFS. Tegaserod unavailable; evidence does not directly apply to prucalopride (assumed class effect). Single-centre. ME/CFS Relevance:: Directly supports the clinical strategy of prokinetic prophylaxis after SIBO eradication in ME/CFS patients with autonomic/MMC dysfunction. Addresses the root-cause gap: without restoring MMC function, antibiotic-treated SIBO will recur within 2–3 months. Certainty Assessment::
- *Quality:* Low--Medium (retrospective, small groups)
- *Sample:* n=64 (subgroups n=16--42)
- *Replication:* Not independently replicated
- *Score:* 0.3516 Deloose et al. 2012 — Migrating Motor Complex: Control and Disease
Full Citation:: Deloose E, Janssen P, Depoortere I, Tack J. The migrating motor complex: control mechanisms and its role in health and disease. Nat Rev Gastroenterol Hepatol. 2012;9(5):271–285. (Deloose et al. 2012) DOI:: 10.1038/nrgastro.2012.57 PMID:: 22450306 Article Type:: Comprehensive narrative review (Nature Reviews) Key Findings::
- MMC is a cyclic fasting motility pattern (4 phases; phase III = powerful peristaltic sweep every 90--120 min)
- MMC absence definitively associated with gastroparesis, intestinal pseudo-obstruction, and SIBO
- Critical mechanistic distinction: vagus nerve modulates *gastric* MMC phase III but does NOT regulate small bowel MMC periodicity (enteric nervous system autonomous)
- Motilin, ghrelin, erythromycin induce antro-duodenal phase III; serotonin and somatostatin induce duodenal-origin phase III
- Scintigraphy and electrophysiology studies confirm enteric autonomy of small bowel MMCConclusion:: MMC dysfunction is a central mechanism linking gut dysmotility to SIBO. The enteric nervous system dominates small bowel MMC; autonomic vagal dysfunction is a contributing but not sufficient cause of MMC failure in ME/CFS. Limitations:: Review article, no primary data. Does not address ME/CFS specifically. Mechanistic understanding of enteric neuropathy in ME/CFS remains incomplete. ME/CFS Relevance:: Establishes the mechanistic foundation for the vagal dysfunction → MMC impairment → SIBO pathway in ME/CFS. Clarifies that the autonomic component is primarily gastric; small bowel MMC failure likely requires additional enteric neuropathy. This nuance prevents oversimplification of the ME/CFS-SIBO pathway. Certainty Assessment::
- *Quality:* High (Nature Reviews Gastroenterology, comprehensive and widely cited)
- *Sample:* Review (no primary cohort)
- *Replication:* Mechanisms well-replicated in referenced primary studies
- *Score:* 0.8017 Szabo et al. 2014 — H2S and Mitochondrial Complex IV Inhibition
Full Citation:: Szabo C, Ransy C, Módis K, Andriamihaja M, Murghes B, Coletta C, Olah G, Yanagi K, Bouillaud F. Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part I. Biochemical and physiological mechanisms. Br J Pharmacol. 2014;171(8):2099–2122. (Szabo et al. 2014) DOI:: 10.1111/bph.12369 PMID:: 23991830 Article Type:: Biochemical review with experimental evidence Key Findings::
- H2S has a biphasic (bell-shaped) relationship with mitochondrial function
- At low-physiological concentrations: H2S donates electrons via sulfide:quinone oxidoreductase (SQR) → stimulates electron transport chain → increases ATP production
- At high-toxic concentrations: H2S competitively binds to cytochrome a3 prosthetic group of Complex IV (cytochrome c oxidase) → blocks O2 binding → electron backup throughout ETC → inner membrane potential collapses → aerobic ATP synthesis ceases
- Mechanism is functionally identical to cyanide poisoning at high doses
- Colonocytes normally metabolise H2S as a barrier, preventing systemic absorption; intestinal sulfide overproduction (ISO) overwhelms this protection
- SQR-mediated H2S oxidation integrates H2S into the ETC as an electron donor — dual substrate and inhibitor depending on concentrationConclusion:: H2S-dominant SIBO (ISO) creates a local gut environment of chronically elevated H2S that, when systemic exposure occurs, directly inhibits mitochondrial Complex IV with consequences for ATP generation — a plausible mechanism connecting gut dysbiosis to ME/CFS-pattern energy failure. Limitations:: Biochemical review; direct demonstration of SIBO-derived H2S inhibiting patient mitochondria has not been performed in ME/CFS cohorts. The concentration thresholds for stimulation vs inhibition are not fully characterised in vivo. ME/CFS Relevance:: Provides the mechanistic bridge for the SIBO-derived H2S → Complex IV inhibition → reduced aerobic ATP → fatigue pathway. Directly connects the gut-microbiome chapter to the energy-metabolism and mitochondrial dysfunction chapters. H2S-dominant SIBO subtype (ISO) warrants specific identification and treatment in ME/CFS patients with fatigue disproportionate to other findings. Certainty Assessment::
- *Quality:* High (British Journal of Pharmacology, mechanistic review with experimental grounding)
- *Sample:* Biochemical studies (multiple)
- *Replication:* Core mechanism well-replicated; SIBO-ME/CFS application is inference
- *Score:* 0.8018 Rezaie et al. 2017 — North American Consensus on Breath Testing
Full Citation:: Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, Schmulson M, Valdovinos M, Zakko S, Pimentel M. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American Consensus. Am J Gastroenterol. 2017;112(5):775–784. (Rezaie et al. 2017) DOI:: 10.1038/ajg.2017.46 PMID:: 28323273 Article Type:: Expert consensus statement Key Findings::
- 26 consensus statements across five domains: indications, preparation, performance, result interpretation, knowledge gaps
- SIBO positive threshold: hydrogen rise ≥20 ppm by 90 min on glucose or lactulose BT
- Methane (IMO) positive: ≥10 ppm at any time point
- Recommended substrate doses: lactulose 10 g, glucose 75 g, fructose 25 g, lactose 25 g
- Standard 2-gas devices do not measure H2S — identified explicitly as a knowledge gap (predates trio-smart)
- Not recommended for oro-cecal transit measurement (transit-time confounding)Conclusion:: Establishes the diagnostic standard for hydrogen/methane breath testing 2017–present. Explicitly acknowledges H2S as an unmeasured gap, creating the clinical rationale for trio-smart development. Limitations:: Consensus, not systematic review. Lactulose test specificity questioned by subsequent ESNM/ANMS critique (Kashyap 2024). H2S/ISO detection still requires specialised equipment not widely available. Consensus group includes Pimentel, whose commercial ties to breath test technology represent a potential COI. ME/CFS Relevance:: Defines the diagnostic standards that should be applied when breath testing ME/CFS patients for SIBO. Critical for interpreting the Karhu 2023 prevalence data. The H2S gap means existing ME/CFS prevalence studies may systematically undercount ISO-dominant patients. Certainty Assessment::
- *Quality:* High (multi-expert consensus, American Journal of Gastroenterology)
- *Sample:* Expert consensus (no primary cohort)
- *Replication:*: Widely adopted as standard; partially critiqued by Kashyap 2024
- *Score:* 0.7519 Pimentel et al. 2020 — ACG Clinical Guideline: SIBO
Full Citation:: Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol. 2020;115(2):165–178. (Pimentel et al. 2020) DOI:: 10.14309/ajg.0000000000000501 PMID:: 32023228 Article Type:: Clinical practice guideline (GRADE methodology) Key Findings::
- GRADE-based guideline covering diagnosis, testing, and treatment of SIBO
- Breath testing recommended for IBS, symptomatic motility disorders, and post-GI-surgery patients
- Rifaximin 550 mg TID × 14 days: first-line for H2-dominant SIBO
- Rifaximin + neomycin: for CH4-dominant (intestinal methanogenic overgrowth, IMO)
- Nutrient malabsorption mechanisms documented: vitamin B12 (bacterial competitive consumption before intrinsic-factor-bound B12 reaches terminal ileum), fat-soluble vitamins A/D/E/K (bacterial deconjugation of bile salts → fat maldigestion), iron (mucosal inflammation + competitive uptake)
- Prokinetics post-eradication mentioned as prevention strategy
- Predisposing conditions include motility disorders, anatomical abnormalities, immunodeficiency — all relevant to ME/CFSConclusion:: Comprehensive evidence-based guidance for SIBO management applicable to ME/CFS patients with GI comorbidity. Formalises the nutrient malabsorption consequences that compound ME/CFS-related deficiency burden. Limitations:: GRADE evidence base is limited for many recommendations; much relies on expert opinion. First-author (Pimentel) has commercial interest in SIBO breath testing field. H2S/ISO not yet addressed (predates wider trio-smart use). ME/CFS Relevance:: Gold-standard reference for SIBO treatment decisions in ME/CFS clinic. Nutrient malabsorption section directly explains why ME/CFS patients with untreated SIBO accumulate B12, iron, and fat-soluble vitamin deficiencies that worsen fatigue, cognitive symptoms, and immune dysfunction independent of primary ME/CFS pathology. Certainty Assessment::
- *Quality:* High (ACG official guideline, GRADE methodology)
- *Sample:* Guideline (synthesises multiple studies)
- *Replication:*: Widely adopted; evidence graded per GRADE
- *Score:* 0.8020 Wielgosz-Grochowska et al. 2024 — SIBO Subtypes and Nutritional Status
Full Citation:: Wielgosz-Grochowska JP, Domanski N, Drywien ME. Identification of SIBO subtypes along with nutritional status and diet as key elements of SIBO therapy. Int J Mol Sci. 2024;25(13):7341. (Wielgosz-Grochowska, Domanski, and Drywien 2024) DOI:: 10.3390/ijms25137341 PMID:: 39000446 Article Type:: Observational cross-sectional study Key Findings::
- n=67 newly diagnosed SIBO patients: H+ 18%, M+ 31%, H+/M+ mixed 51%
- H+/M+ group: lowest serum vitamin D, lowest serum ferritin (iron stores), highest dietary fat intake; most pronounced deficiency burden
- M+ group: elevated serum folate (bacterial production of folate as byproduct), reduced fibre intake
- H+ group: primary abnormality was reduced lactose tolerance
- 87--97% of all subtypes below vitamin D adequate intake threshold
- Over 70% of M+ and H+/M+ groups consumed excessive dietary fat
- Conclusion: SIBO subtype determines specific nutritional deficiency profile; subtype-guided supplementation requiredConclusion:: SIBO subtype is clinically meaningful for nutritional assessment. Mixed H+/M+ patients carry the greatest deficiency burden, particularly for vitamin D and iron — nutrients already commonly deficient in ME/CFS. Limitations:: Small n (67), single-centre (Warsaw, Poland), observational design with no control group. Not ME/CFS-specific. Polish cohort dietary patterns may not generalise. Serum vitamin D reflects sun exposure and supplementation as well as gut absorption. ME/CFS Relevance:: Quantifies subtype-specific deficiency profiles directly relevant to ME/CFS patients with SIBO comorbidity. Low ferritin and vitamin D in the mixed subtype compound the energy-metabolism and immune-dysfunction burden in ME/CFS. Supports routine subtype testing and targeted repletion rather than empirical supplementation alone. Certainty Assessment::
- *Quality:* Medium (observational, single-centre, small n)
- *Sample:* n=67
- *Replication:* Not independently replicated
- *Score:* 0.45